Geode Capital Management’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $913K | Sell |
103,270
-116,687
| -53% | -$1.03M | ﹤0.01% | 3353 |
|
|
2025
Q1 | $2.37M | Buy |
219,957
+13,094
| +6% | +$141K | ﹤0.01% | 2973 |
|
|
2024
Q4 | $2.65M | Buy |
206,863
+5,865
| +3% | +$75.1K | ﹤0.01% | 3034 |
|
|
2024
Q3 | $5.55M | Buy |
200,998
+395
| +0.2% | +$10.9K | ﹤0.01% | 2704 |
|
|
2024
Q2 | $5.82M | Sell |
200,603
-248
| -0.1% | -$7.19K | ﹤0.01% | 2643 |
|
|
2024
Q1 | $8.96M | Buy |
200,851
+3,983
| +2% | +$178K | ﹤0.01% | 2390 |
|
|
2023
Q4 | $7.64M | Buy |
196,868
+14,044
| +8% | +$545K | ﹤0.01% | 2480 |
|
|
2023
Q3 | $5.38M | Buy |
182,824
+14,033
| +8% | +$413K | ﹤0.01% | 2600 |
|
|
2023
Q2 | $10.7M | Buy |
168,791
+9,369
| +6% | +$596K | ﹤0.01% | 2247 |
|
|
2023
Q1 | $7.52M | Buy |
159,422
+6,822
| +4% | +$322K | ﹤0.01% | 2428 |
|
|
2022
Q4 | $10.6M | Buy |
152,600
+5,067
| +3% | +$352K | ﹤0.01% | 2234 |
|
|
2022
Q3 | $21.6M | Buy |
147,533
+53,729
| +57% | +$7.88M | ﹤0.01% | 1671 |
|
|
2022
Q2 | $12.2M | Buy |
93,804
+21,092
| +29% | +$2.75M | ﹤0.01% | 2117 |
|
|
2022
Q1 | $7.34M | Buy |
72,712
+44,776
| +160% | +$4.52M | ﹤0.01% | 2569 |
|
|
2021
Q4 | $4.32M | Buy |
27,936
+1,342
| +5% | +$208K | ﹤0.01% | 2974 |
|
|
2021
Q3 | $7.87M | Buy |
26,594
+17,873
| +205% | +$5.29M | ﹤0.01% | 2640 |
|
|
2021
Q2 | $2.83M | Buy |
+8,721
| New | +$2.83M | ﹤0.01% | 3163 |
|